Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131973 · ClinicalTrials.gov registry record · Phase 1
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03131973 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 26 participants.
The verdict
NCT03131973, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Drug-drug interaction study in healthy men and women not of childbearing potential. Assess the effect of BMS-986195 on the pharmacokinetics of methotrexate, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin. Collect data on safety of BMS-986195 and methotrexate, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin. Collect data on multiple-dose pharmacodynamics of BMS-986195.
Interventions
- DRUG Leucovorin
- DRUG Montelukast
- DRUG Methotrexate
- DRUG Caffeine
- DRUG BMS-986195
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-05-13 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03131973
The ClinicalTrials.gov registry entry for NCT03131973 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.
NCT03131973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03131973 about?
NCT03131973 is a clinical study titled "Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin". Drug-drug interaction study in healthy men and women not of childbearing potential. Assess the effect of BMS-986195 on the pharmacokinetics of methotrexate, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin. Collect data on safety of BMS-986195 and methotrexate, ca...
What is the current status of trial NCT03131973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-05-13. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT03131973?
The interventions under investigation include: Leucovorin (DRUG), Montelukast (DRUG), Methotrexate (DRUG), Caffeine (DRUG), BMS-986195 (DRUG).
Who is sponsoring clinical trial NCT03131973?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.